Alzheimer's biotech Alzheon nets $50M Series D

A Framingham, MA-based biotech has some new cash to play with.

Alzheon announced Thursday morning it has completed a $50 million Series D round aimed to advance a Phase III study for its oral Alzheimer’s program, as well as to help prep the drug’s regulatory filings. The candidate, dubbed ALZ-801, is an oral tablet being evaluated for patients with early-stage Alzheimer’s disease.